Drugs / CRD-TMH-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514249 | Aug 2022 → Sep 2023 | Duchenne muscular dystrophy | Cure Rare Disease, Inc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRD-TMH-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05514249 ↗ |
| Route | Intravenous | “administered via intravenous injection” NCT05514249 ↗ |